Advertisement

Topics

NICE greenlights Celgene pancreatic cancer drug as first-line combination treatment

05:22 EDT 4 Aug 2017 | Pharmafile

Celgene is celebrating following NICE’s announcement that it had decided to recommend the use of nab-Paclitaxel, when used in combination with gemcitabine, as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC), or metastatic pancreatic cancer. This treatment option will now be made available for patients on the NHS in England and Wales.   

read more

Original Article: NICE greenlights Celgene pancreatic cancer drug as first-line combination treatment

NEXT ARTICLE

More From BioPortfolio on "NICE greenlights Celgene pancreatic cancer drug as first-line combination treatment"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pancreatic Cancer
The pancreas secretes a number of important hormones into the digestive tract and the blood stream. Cancers are most commonly exocrine than endocrine (neuroendocrine) tumors. Functional tumors secrete hormones; Insulinoma, Gastrinoma, Somatostatinoma, VI...

Pancreatitis
Pancreatitis Acute pancreatitis is inflammation of the pancreas caused by the release of activated pancreatic enzymes. Common triggers are biliary tract disease and chronic heavy alcohol intake.  Diagnosis is based on clinical presentation...